INM
Price
$2.22
Change
+$0.04 (+1.83%)
Updated
Aug 29 closing price
Capitalization
4.44M
PYPD
Price
$3.35
Change
-$0.03 (-0.89%)
Updated
Aug 29 closing price
Capitalization
53.26M
65 days until earnings call
Interact to see
Advertisement

INM vs PYPD

Header iconINM vs PYPD Comparison
Open Charts INM vs PYPDBanner chart's image
InMed Pharmaceuticals
Price$2.22
Change+$0.04 (+1.83%)
Volume$26.81K
Capitalization4.44M
PolyPid
Price$3.35
Change-$0.03 (-0.89%)
Volume$20.94K
Capitalization53.26M
INM vs PYPD Comparison Chart in %
Loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PYPD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INM vs. PYPD commentary
Sep 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INM is a Buy and PYPD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 01, 2025
Stock price -- (INM: $2.22 vs. PYPD: $3.35)
Brand notoriety: INM and PYPD are both not notable
INM represents the Pharmaceuticals: Generic, while PYPD is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: INM: 19% vs. PYPD: 22%
Market capitalization -- INM: $4.44M vs. PYPD: $53.26M
INM [@Pharmaceuticals: Generic] is valued at $4.44M. PYPD’s [@Biotechnology] market capitalization is $53.26M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $69.31B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INM’s FA Score shows that 0 FA rating(s) are green whilePYPD’s FA Score has 1 green FA rating(s).

  • INM’s FA Score: 0 green, 5 red.
  • PYPD’s FA Score: 1 green, 4 red.
According to our system of comparison, PYPD is a better buy in the long-term than INM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INM’s TA Score shows that 5 TA indicator(s) are bullish while PYPD’s TA Score has 4 bullish TA indicator(s).

  • INM’s TA Score: 5 bullish, 3 bearish.
  • PYPD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INM is a better buy in the short-term than PYPD.

Price Growth

INM (@Pharmaceuticals: Generic) experienced а -2.63% price change this week, while PYPD (@Biotechnology) price change was -4.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.55%. For the same industry, the average monthly price growth was +67.47%, and the average quarterly price growth was +80.21%.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

PYPD is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.55% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PYPD($53.3M) has a higher market cap than INM($4.45M). PYPD YTD gains are higher at: 10.197 vs. INM (-51.634). INM has higher annual earnings (EBITDA): -7.86M vs. PYPD (-33.1M). PYPD has more cash in the bank: 29.5M vs. INM (4.68M). INM has less debt than PYPD: INM (849K) vs PYPD (8.67M). INM has higher revenues than PYPD: INM (4.92M) vs PYPD (0).
INMPYPDINM / PYPD
Capitalization4.45M53.3M8%
EBITDA-7.86M-33.1M24%
Gain YTD-51.63410.197-506%
P/E Ratio0.01N/A-
Revenue4.92M0-
Total Cash4.68M29.5M16%
Total Debt849K8.67M10%
FUNDAMENTALS RATINGS
INM: Fundamental Ratings
INM
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
84
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INMPYPD
RSI
ODDS (%)
Bullish Trend 4 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
84%
Bullish Trend 15 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PYPD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCRT2.130.03
+1.43%
Alaunos Therapeutics Inc.
DOC17.940.08
+0.45%
Healthpeak Properties
WLYB39.85N/A
N/A
John Wiley & Sons
ARCT17.01-0.29
-1.68%
Arcturus Therapeutics Holdings
ORGN0.53-0.03
-5.58%
Origin Materials

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with TTNP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then TTNP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
+1.83%
TTNP - INM
45%
Loosely correlated
-0.75%
HYPD - INM
39%
Loosely correlated
-7.99%
OMER - INM
36%
Loosely correlated
-1.65%
VTYX - INM
31%
Poorly correlated
-2.04%
RVPH - INM
30%
Poorly correlated
-2.24%
More

PYPD and

Correlation & Price change

A.I.dvisor tells us that PYPD and AMLX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and AMLX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYPD
1D Price
Change %
PYPD100%
-0.89%
AMLX - PYPD
29%
Poorly correlated
-0.42%
INM - PYPD
28%
Poorly correlated
+1.83%
VRAX - PYPD
28%
Poorly correlated
-1.48%
SER - PYPD
27%
Poorly correlated
+3.70%
PRTA - PYPD
27%
Poorly correlated
-0.49%
More